Zobrazeno 1 - 10
of 34
pro vyhledávání: ''
Autor:
Claudia Alessandra Andrade de Paula, Debora Okamoto, Sheila Siqueira Andrade, Mariana Cristina Cabral Silva, Lilian Caroline Gonçalves de Oliveira, Maria Luiza Vilela Oliva, Gil Facina, Giovani B. Peres, Ismael Dale Cotrim Guerreiro da Silva, Tatiana F. Ottaiano, Eloísa Dognani Castro, Antonio Campos, Afonso Celso Pinto Nazário, Edgar J. Paredes-Gamero, Manoel João Batista Castello Girão, Maria A. Juliano, Iuri E. Gouvea
Publikováno v:
BMC Cancer
Background Breast cancer comprises clinically and molecularly distinct tumor subgroups that differ in cell histology and biology and show divergent clinical phenotypes that impede phase III trials, such as those utilizing cathepsin K inhibitors. Here
Autor:
Nicole Lavender, Jiqing Sai, Ann Richmond, Philip Owens, Jinming Yang, C. Andrew Johnson, Gregory D. Ayers, Sheau-Chiann Chen
Publikováno v:
BMC Cancer
Background The role of the chemokine CCL2 in breast cancer is controversial. While CCL2 recruits and activates pro-tumor macrophages, it is also reported to enhance neutrophil-mediated anti-tumor activity. Moreover, loss of CCL2 in early development
Publikováno v:
BMC Cancer
Background Although mammary microcalcification is frequently observed and has been associated with poor survival in patients with breast cancer, the genesis of calcification remains unclear. Carbonic anhydrase I (CA1) has been shown to promote calcif
Publikováno v:
BMC Cancer
Background Monoclonal antibodies have been used to effectively treat various tumors. We previously established a unique strategy to identify tumor specific antibodies by capturing B-cell response against breast tumor antigens from patient-derived sen
Publikováno v:
BMC Cancer
Background Breast cancer is one of the most deadly diseases in women. Inhibiting the synthesis of estrogen is effective in treating patients with estrogen-responsive breast cancer. Previous studies have demonstrated that use of cyclooxygenase (COX) i
Autor:
Gina Bouchard, Yves Bérubé-Lauzière, Hélène Therriault, Sameh Geha, Rachel Bujold, Caroline Saucier, Benoit Paquette
Publikováno v:
BMC Cancer
Background Some triple negative breast cancer (TNBC) patients are at higher risk of recurrence in the first three years after treatment. This rapid relapse has been suggested to be associated with inflammatory mediators induced by radiation in health
Autor:
Chiara Campanella, Monica Gatti, Tullio Florio, Valeria Marini, Aldo Pagano, Guendalina Vito, Antonio Daga, Alessandra Pattarozzi, Alessandra Ratto, Francesca Mattioli, Adriana Bajetto, Roberto Würth, Carmen Fucile, Angelo Ferrari, Federica Barbieri, Elisa Carra, Stefano Thellung
Publikováno v:
BMC Cancer
Background Cancer stem cells (CSCs) are considered the cell subpopulation responsible for breast cancer (BC) initiation, growth, and relapse. CSCs are identified as self-renewing and tumor-initiating cells, conferring resistance to chemo- and radio-t
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 380 (2012)
BMC Cancer
BMC Cancer
Background Tumor development is known to be a stepwise process involving dynamic changes that affect cellular integrity and cellular behavior. This complex interaction between genomic organization and gene, as well as protein expression is not yet fu
Publikováno v:
BMC Cancer
Background Matrix metalloproteases and collagen are key participants in breast cancer, but their precise roles in cancer etiology and progression remain unclear. MMP13 helps regulate collagen structure and has been ascribed largely harmful roles in c
Autor:
Hugo M. Horlings, Meaghan Dendy, Tao Su, Lao H. Saal, Neal Rosen, Matthew Maurer, Ramon Parsons, Lorenzo Memeo, Qing-Bai She, Mervi Jumppanen, Jorma Isola, Ying Ka Ingar Lau, Sofia K. Gruvberger-Saal, Marc J. van de Vijver, Yilun Chen, Hanina Hibshoosh
Publikováno v:
BMC cancer, 16(1). BioMed Central
BMC Cancer
BMC Cancer
The basal-like breast cancer (BLBC) subtype is characterized by positive staining for basal mammary epithelial cytokeratin markers, lack of hormone receptor and HER2 expression, and poor prognosis with currently no approved molecularly-targeted thera